A New Approach of Detecting ALK Fusion Oncogenes by RNA Sequencing Exon Coverage Analysis
Authors:
- Galina ZakharovaGalina Zakharova
- Maria SuntsovaMaria Suntsova
- Elizaveta RabushkoElizaveta Rabushko
- Tharaa MohammadTharaa Mohammad
- Alexey DrobyshevAlexey Drobyshev
- Alexander SeryakovAlexander Seryakov
- Elena PoddubskayaElena Poddubskaya
- Alexey MoisseevAlexey Moisseev
- Anastasia SmirnovaAnastasia Smirnova
- Maxim SorokinMaxim Sorokin
- Victor TkachevVictor Tkachev
- Alexander SimonovAlexander Simonov
Open Access
Abstract
Background: In clinical practice, various methods are used to identify ALK gene rearrangements in tumor samples, ranging from “classic” techniques, such as IHC, FISH, and RT-qPCR, to more advanced highly multiplexed approaches, such as NanoString technology and NGS panels. Each of these methods has its own advantages and disadvantages, but they share the drawback of detecting only a restricted (although sometimes quite extensive) set of preselected biomarkers. At the same time, whole transcriptome sequencing (WTS, RNAseq) can, in principle, be used to detect gene fusions while simultaneously analyzing an incomparably wide range of tumor characteristics. However, WTS is not widely used in practice due to purely analytical limitations and the high complexity of bioinformatic analysis, which requires considerable expertise. In particular, methods to detect gene fusions in RNAseq data rely on the identification of chimeric reads. However, the typically low number of true fusion reads in RNAseq limits its sensitivity. In a previous study, we observed asymmetry in the RNAseq exon coverage of the 3′ partners of some fusion transcripts. In this study, we conducted a comprehensive evaluation of the accuracy of ALK fusion detection through an analysis of differences in the coverage of its tyrosine kinase exons. Methods: A total of 906 human cancer biosamples were subjected to analysis using experimental RNAseq data, with the objective of determining the extent of asymmetry in ALK coverage. A total of 50 samples were analyzed, comprising 13 samples with predicted ALK fusions and 37 samples without predicted ALK fusions. These samples were assessed by targeted sequencing with two NGS panels that were specifically designed to detect fusion transcripts (the TruSight RNA Fusion Panel and the OncoFu Elite panel). Results: ALK fusions were confirmed in 11 out of the 13 predicted cases, with an overall accuracy of 96% (sensitivity 100%, specificity 94.9%). Two discordant cases exhibited low ALK coverage depth, which could be addressed algorithmically to enhance the accuracy of the results. It was also important to consider read strand specificity due to the presence of antisense transcripts involving parts of ALK. In a limited patient sample undergoing ALK-targeted therapy, the algorithm successfully predicted treatment efficacy. Conclusions: RNAseq exon coverage analysis can effectively detect ALK rearrangements.Keywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation (075-15-2022-304, 20-75-10071)
- Russian Science Foundation (075-15-2022-304, 20-75-10071)
This publication has 75 references indexed in Scilit:
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Diagnosis of Fusion-Associated Sarcomas by Exon Expression Imbalance and Gene ExpressionThe Journal of Molecular Diagnostics, 2022
- Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study groupJournal of the National Cancer Center, 2021
- Clinical Implications of a Targeted RNA-Sequencing Panel in the Detection of Gene Fusions in Solid TumorsThe Journal of Molecular Diagnostics, 2021
- A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discoveryCell Systems, 2021
- Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLCMolecular Diagnosis & Therapy, 2021
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2020
- Diagnostic yield of NanoString nCounter FusionPlex profiling in soft tissue tumorsGenes, Chromosomes and Cancer, 2020
- ALK and ROS1 testing on lung cancer cytologic samples: PerspectivesCancer Cytopathology, 2017
- Anaplastic lymphoma kinase inhibitorsCurrent Opinion in Pharmacology, 2015